A differential diagnosis must be made between transient yellow discoloration of the nails and yellow nail syndrome. We highlight some practical aspects of yellow nail discoloration.
Sir,
We read with great interest the article by Vignes et al. recently published by the journal [1].
Anzeige
We would like to add some practical issues related to differential diagnosis of yellow nail discoloration.
A differential diagnosis must be made between transient yellow discoloration of the nails and yellow nail syndrome.
Yellow discoloration of the nails has been reported as an adverse reaction after some drugs such as: quinaqrine used for cutaneous lupus erythematosus [2], after topical use of 5-fluorouracil for the treatment of nail psoriasis (Fig. 1) [3], temsirolimus [4], or bucillamine for rheumatoid arthritis [5], retinoids [6] (Fig. 2). Furthermore, yellow discoloration of the nails has been described during hemodialysis [7], in patients diagnosed with non-Hodgkin lymphoma [8]. Yellow nails can be also observed in patients diagnosed with diabetes mellitus (Fig. 3a, b) [9], tobacco-associated use (Fig. 4), or after intense use of nail polish remover (Fig. 5). In recent years, skin adverse reactions induced by cetuximab have been lately reported; cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR) used in the treatment of colorectal cancer [10]. Recently, yellowish distal discoloration was observed in our department in a 67-year-old female patient treated with cetuximab for colorectal cancer (Fig. 6).
Fig. 1
Diffuse yellow discoloration of the nail plate in a case of nail psoriasis treated with topical 5-fluorouracil (close view)
Fig. 2
Yellowish discoloration of finger nails in a teenager while treated with systemic isotretinoin for acne
Fig. 3
“Diabetic yellow nails” (a) and yellow-green discoloration of a nail in a diabetic patient due to Pseudomonas aeruginosa infection (b)
Fig. 4
Tobacco associated yellow nails
Fig. 5
Transient yellow discoloration as a result of nail polish remover (acetone)
Fig. 6
Distal yellowish discoloration of the nail during treatment with cetuximab
×
×
×
×
×
×
Acknowledgements
Not applicable.
Anzeige
Funding
None reported.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All the patients consented to the publishing of the photos containing non-identifiable images.
Consent for publication
All the patients consented to the publishing of the photos containing non-identifiable images.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
